Adaptin Bio (APTN) Cash from Operations (2023 - 2026)

Adaptin Bio (APTN) has 4 years of Cash from Operations data on file, last reported at 596298.0 in Q1 2026.

• For the quarter ending Q1 2026, Cash from Operations rose 73.85% year-over-year to 596298.0; the trailing twelve-month figure through Mar 2026 stood at 3094314.0 (down 8.98% YoY), and the FY2025 full-year result was 4777892.0, down 635.87% from the prior year.
• Cash from Operations grew to 596298.0 in Q1 2026, from 702876.0 in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of 112653.0 in Q4 2024 to a low of 2279876.0 in Q1 2025.
• A 4-year average of 608182.0 and a median of 532357.0 in 2024 frame the typical range for Cash from Operations.
• Across the five-year window, Cash from Operations surged 293.07% in 2024 and sank 2441.81% in 2025, its largest moves.
• Tracing APTN's Cash from Operations over 4 years: stood at 58347.0 in 2023, then surged by 293.07% to 112653.0 in 2024, then sank by 723.93% to 702876.0 in 2025, then grew by 15.16% to 596298.0 in 2026.
• Business Quant data shows APTN's Cash from Operations at 596298.0 in Q1 2026, 702876.0 in Q4 2025, and 772430.0 in Q3 2025.